AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 211 min read$MOBI

Tansey Casey M purchased $199K of MOBI

Tansey Casey M purchased 16,441 shares of Mobia Medical, Inc. (MOBI) at $12.07 ($0.20M total) on 2026-08-18.

Original reporting
SEC EDGAR · Tansey Casey M
Published Aug 21, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$MOBI
Neutral
medium confidence
Mentioned
$MOBI
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MOBINeutralLow
01

Why it matters

The director's purchase adds a modest positive data point but is unlikely to shift market perception significantly.

02

Market read

Small insider buy; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 5/10Novelty 4/10Timing: today

Background

Form 4 filings disclose insider transactions; investors monitor them for signals of insider confidence.

Company-level read

Ticker impact

$MOBINeutralMedium confidence
Context

Director Tansey Casey purchased 16,441 shares of Mobia Medical for $198,523, a new Form 4 filing.

Expected impact

Limited short-term price lift, unlikely to move the stock materially.

Evidence & confidence

A $199K buy by a director is a positive signal but small; market may price it in quickly.

Market effects

Sector

Minor signal for the medical device sector; no broader impact.

Regional

U.S. market only; no regional ripple.

Global

Low

Counterpoint

What could challenge this read

The purchase may be routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Company
    Mobia Medical, Inc.

    U.S.-listed medical device company.

  • Insider
    Tansey Casey

    Director of Mobia Medical.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MOBI insider trading history →

Related articles

AUG 28
$MOBIHigh

Mobia Medical stock jumps on stroke guideline inclusion

Mobia Medical Inc (MOBI) shares rose 7.2% premarket after the American Heart Association included its paired vagus nerve stimulation in 2026 stroke rehabilitation guidelines. The Vivistim Paired VNS System is the only FDA-approved system for this treatment, which may improve upper-limb function. Stroke is a leading cause of long-term disability in the U.S.

investing.com1 min
AUG 19
$MOBIMedAI 8/10

Mobia Medical (MOBI) Q2 2026 Earnings Call Transcript

Mobia Medical (MOBI) reported Q2 2026 revenue of $13.5M, up 102% YoY, driven by Vivistim system adoption. Full-year guidance set at $54M-$56M. Net loss was $21M, with cash reserves of $177.1M post-IPO. Management plans to expand active territories and target 1,500 U.S. stroke centers.

fool.com7 min
AUG 11
$MOBIMed

Mobia Medical, Inc. (MOBI): Results of Operations and Financial Condition

Mobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mobia Medical Reports Second Quarter 2026 Financial Results Austin, Texas, August 11, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today reported financial re

SEC EDGAR 8-K4 min
JUL 14
$MOBIMedAI 8/10

Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy

Mobia Medical (Nasdaq: MOBI) said Neurology published two-year follow-up results from its VNS-REHAB trial of Vivistim Paired VNS Therapy in chronic ischemic stroke. Among 49 participants, 76% met response on FMA-UE and/or WMFT, with average gains of +7.5 FMA-UE and +0.63 WMFT. Mobia reported improvements in daily living and quality of life sustained for at least two years.

manilatimes.net4 min